Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.43 |
| ▸ | PTPRC | P08575 | 6/20 | 0.42 |
| ▸ | PTPN13 | Q12923 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407802 | 0.89 | APEX1 (0.64) | APEX1PDK2PTPRCPTPN13MAPT | |
| SCHEMBL29441935 | 0.89 | APEX1 (0.64) | APEX1PDK2PTPRCPTPN13MAPT | |
| SCHEMBL29407803 | 0.89 | APEX1 (0.64) | APEX1PDK2PTPRCPTPN13MAPT | |
| SCHEMBL7627154 | 0.89 | APEX1 (0.64) | APEX1PDK2PTPRCPTPN13MAPT | |
| SCHEMBL15691742 | 0.87 | APEX1 (0.62) | APEX1PDK2PTPRCPTPN13MAPT | |
| SCHEMBL17051271 | 0.87 | APEX1 (0.62) | APEX1PDK2PTPRCPTPN13MAPT | |
| SCHEMBL26017056 | 0.84 | APEX1 (0.51) | APEX1PDK2MAPTALDH1A1ITGA4 | |
| SCHEMBL28567585 | 0.83 | APEX1 (0.76) | APEX1PDK2MAPTALDH1A1ITGA4 | |
| SCHEMBL15691563 | 0.83 | APEX1 (0.56) | APEX1PDK2PTPRCPTPN13MAPT | |
| SCHEMBL17050258 | 0.82 | APEX1 (0.55) | APEX1PDK2PTPRCPTPN13MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230243837-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | APEX1 187/4885PDK2 4772/4885PTPRC 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.